

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E21/22 - Hormones 2

Deadline: 08.02.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(393) C-peptide					35							26	26	100%
Samples and groups	[pmol/L]													
Sample A		389	91	23	35							26	26	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		382	8,9	2,3	9	0	CVPG	379	11	20%	303	455	9	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		456	18	3,8	15	0	CVPG	456	10	20%	364	548	15	
Other					11	0							2	
														3x 4/12, 2x 4/29, 3x 4/162, 1x 4/164, 2x 4/179
Sample B		173	37	21	35							26	26	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		155	18	11	9	0	CVPG	153	12	20%	122	184	9	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		202	7,0	3,5	15	0	CVPG	202	4,4	20%	161	243	15	
Other					11	3							2	
														3x 4/12, 2x 4/29, 3x 4/162, 1x 4/164, 2x 4/179
(193) Ferritin					46							44	43	98%
Samples and groups	[µg/L]													
Sample A		121	25	20	46							44	43	98%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		131	9,3	7,1	9	0	CVPG	136	3,9	24%	103	169	9	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		137	15	11	13	0	CVPG	141	2,1	24%	107	175	13	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		97,4	16	16	5	0	CVPG	95	3,2	24%	72,2	118	5	
Other					19	0							17	
														3x 4/12, 3x 4/29, 1x 4/149, 3x 4/179, 2x 6/1, 4x 6/58, 3x 6/60
Sample B		37,9	8,6	23	46							44	44	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		37,0	6,2	17	9	0	CVPG	37,7	1,4	±16,8	20,9	54,5	9	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		43,3	4,6	11	13	0	CVPG	45,9	0,76	±16,8	29,1	62,7	13	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		27,9	1,3	4,8	5	0	CVPG	28,9	1,1	±16,8	12,1	45,7	5	
Other					19	0							17	
														3x 4/12, 3x 4/29, 1x 4/149, 3x 4/179, 2x 6/1, 4x 6/58, 3x 6/60
(321) FSH					38							38	35	92%
Samples and groups	[U/L]													
Sample A		8,86	0,83	9,4	38							38	37	97%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		8,29	0,16	1,9	9	0	CVPG	8,32	0,10	15%	7,07	9,57	9	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		8,85	0,67	7,5	7	0	CVPG	9,03	0,17	15%	7,67	10,4	7	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		8,52	0,47	5,5	13	0	CVPG	8,61	0,048	15%	7,31	9,91	13	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		10,3	0,067	0,64	5	0	CVPG	10	0,15	15%	8,5	11,5	5	
Other					4	0							4	
														4x 4/179
Sample B		15,3	1,3	8,2	38							38	36	95%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		14,8	0,67	4,5	9	0	CVPG	14,5	0,15	15%	12,3	16,7	9	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		16,8	2,7	16	7	0	CVPG	16,6	0,39	15%	14,1	19,1	7	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		14,8	0,77	5,2	13	0	CVPG	14,9	0,078	15%	12,6	17,2	13	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		17,5	0,42	2,4	5	0	CVPG	17	0,27	15%	14,4	19,6	5	
Other					4	0							4	
														4x 4/179
(328) hGH					11							10	10	100%
Samples and groups	[mU/L]													
Sample A		41,2	2,5	6,1	11							10	10	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		41,0	1,6	3,8	6	0	CVPG	41	0,65	19%	33,2	48,8	6	
Other					5	0							4	
														1x 1/36, 1x 4/12, 2x 4/60, 1x 4/183
Sample B		3,01	0,46	15	11							10	10	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		3,08	0,27	8,7	6	0	CVPG	3,09	0,047	±1,54	1,55	4,63	6	
Other					5	0							4	
														1x 1/36, 1x 4/12, 2x 4/60, 1x 4/183

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E21/22 - Hormones 2

Deadline: 08.02.2022

Test	[unit]						Comparability							N _{eva}	N _{suc}	S _{rel}	
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL						
(329) IGF-1																	
— Samples and groups	[µg/L]				14									14	14	100%	
Sample A														14	14	100%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		534	190	35	14									14	14	100%	
Other					9	0								9			
							1x 1/36, 3x 4/60, 4x 4/164, 1x 4/183										
Sample B		126	25	20	14									14	14	100%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		145	6,7	4,6	5	0	CVPG	146	2,5	22%	113	179		5			
Other					9	0								9			
							1x 1/36, 3x 4/60, 4x 4/164, 1x 4/183										
(392) IGF-BP3					4									3	3	100%	
— Samples and groups	[µg/L]																
Sample A		3500	1000	29	4									3	3	100%	
Other					4	0								3			
							1x 1/36, 2x 4/29, 1x 4/60										
Sample B		3570	870	25	4									3	3	100%	
Other					4	0								3			
							1x 1/36, 2x 4/29, 1x 4/60										
(325) Insulin					9									9	9	100%	
— Samples and groups	[mU/L]																
Sample A		78,9	8,6	11	9									9	9	100%	
Other					9	0								9			
							2x 4/1, 1x 4/12, 4x 4/60, 1x 4/162, 1x 4/179										
Sample B		17,0	1,4	8,3	9									9	9	100%	
Other					9	0								9			
							2x 4/1, 1x 4/12, 4x 4/60, 1x 4/162, 1x 4/179										
(326) Folate					44									0			
— Samples and groups	[nmol/L]																
Sample A		9,99	1,9	19	44									44	42	95%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		11,3	1,3	12	14	0	CVPG	11,2	0,37	27%	8,17	14,3		14			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		11,1	0,73	6,6	7	0	CVPG	11,1	0,29	27%	8,1	14,1		7			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		8,27	1,3	16	15	0	CVPG	7,88	0,15	27%	5,75	10,1		15			
Other					8	0								8			
							1x 4/29, 1x 4/149, 4x 4/162, 2x 4/179										
Sample B		57,7	19	33	44									0			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		66,2	27	40	14	1	CVPG	62,5	6,6	27%	45,6	79,4		0			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		54,9	2,0	3,6	7	1	CVPG	54,4	0,40	27%	39,7	69,1		0			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		45,4	0,160	0,36	15	1	CVPG	45,4	0,0047	27%	33,1	57,7		0			
Other					8	0								0			
							1x 4/29, 1x 4/149, 4x 4/162, 2x 4/179										
(320) LH					37									37	35	95%	
— Samples and groups	[U/L]																
Sample A		30,1	4,9	16	37									37	35	95%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		25,6	0,82	3,2	9	0	CVPG	25,2	0,35	15%	21,4	29		9			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		24,5	1,3	5,4	7	0	CVPG	24,3	0,43	15%	20,6	28		7			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		34,0	1,0	3,0	12	0	CVPG	34,1	0,19	15%	28,9	39,3		12			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		33,9	0,60	1,8	5	0	CVPG	33,3	0,50	15%	28,3	38,3		5			
Other					4	0								4			
							4x 4/179										
Sample B		7,96	1,9	23	37									37	36	97%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		5,96	0,23	3,9	9	0	CVPG	5,94	0,069	15%	5,04	6,84		9			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		7,83	0,56	7,2	7	0	CVPG	7,64	0,16	15%	6,49	8,79		7			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		9,86	0,49	4,9	12	0	CVPG	9,86	0,061	15%	8,38	11,4		12			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		7,51	0,29	3,9	5	0	CVPG	7,49	0,16	15%	6,36	8,62		5			
Other					4	0								4			
							4x 4/179										
(407) Parathyroid hormone (PTH 1-84)					12									12	10	83%	
— Samples and groups	[pmol/L]																
Sample A		0,896	0,21	24	12									12	10	83%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		0,953	0,14	15	10	0	CVPG	0,958	0,079 ± 0,212	0,754	1,17		10				
Other					2	0								2			
							2x 4/164										
Sample B		0,583	0,0050	0,91	12									12	12	100%	

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E21/22 - Hormones 2

Deadline: 08.02.2022

Test	[unit]					Comparability								
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(327) Vitamin B12					40							40	39	98%
--- Samples and groups ---	[pmol/L]													
Sample A		631	80	13	40							40	39	98%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		535	83	15	8	0	CVPG	536	14	20%	428	644		8
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		673	24	3,6	11	0	CVPG	675	4,4	20%	540	810		11
Other					8	0								8
								3x 4/29, 1x 4/149, 3x 4/162, 1x 4/179						
Sample B		871	120	14	40							40	40	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		901	69	7,6	13	0	CVPG	919	18	20%	735	1110		13
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		712	110	15	8	0	CVPG	753	24	20%	602	904		8
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		919	39	4,2	11	0	CVPG	919	5,6	20%	735	1110		11
Other					8	0								8
								3x 4/29, 1x 4/149, 3x 4/162, 1x 4/179						
(319) Vitamin B12 (active)					9							0		
--- Samples and groups ---	[pmol/L]													
Sample A		224	120	52	9							0		
Other					9	1						0		
								3x 4/1, 2x 4/60, 2x 4/162, 2x 4/179						
Sample B		231	130	55	9							0		
Other					9	1						0		
								3x 4/1, 2x 4/60, 2x 4/162, 2x 4/179						

st_kn_p

End of report

Printed: 16.02.2022